These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35193833)

  • 61. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.
    Kang J; Chen MH; Zhang Y; Moran BJ; Dosoretz DE; Katin MJ; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e463-7. PubMed ID: 21944463
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer.
    Rohrmann S; Roberts WW; Walsh PC; Platz EA
    Prostate; 2003 May; 55(2):140-6. PubMed ID: 12661039
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Vidal AC; Howard LE; Sun SX; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Freedland SJ
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):72-78. PubMed ID: 27698439
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
    Kane CJ; Bassett WW; Sadetsky N; Silva S; Wallace K; Pasta DJ; Cooperberg MR; Chan JM; Carroll PR
    J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Obesity is Associated with Upgrading in Prostate Cancers.
    Sungur M; Çalışkan S
    Folia Med (Plovdiv); 2018 Jun; 60(2):221-225. PubMed ID: 30355830
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diabetes and prostate cancer risk in the REDUCE trial.
    Wu C; Moreira DM; Gerber L; Rittmaster RS; Andriole GL; Freedland SJ
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):326-31. PubMed ID: 21709690
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
    Bañez LL; Hamilton RJ; Partin AW; Vollmer RT; Sun L; Rodriguez C; Wang Y; Terris MK; Aronson WJ; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    JAMA; 2007 Nov; 298(19):2275-80. PubMed ID: 18029831
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer.
    Kok DE; van Roermund JG; Aben KK; van de Luijtgaarden MW; Karthaus HF; van Vierssen Trip OB; Kampman E; Alfred Witjes J; Kiemeney LA
    World J Urol; 2011 Oct; 29(5):695-701. PubMed ID: 21161536
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
    J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of BMI on primary treatment of prostate cancer.
    Davies BJ; Walsh TJ; Ross PL; Knight SJ; Sadetsky N; Carroll PR; Kane CJ
    Urology; 2008 Aug; 72(2):406-11. PubMed ID: 18267336
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Influence of obesity on tumour volume in patients with prostate cancer.
    Capitanio U; Suardi N; Briganti A; Gallina A; Abdollah F; Lughezzani G; Salonia A; Freschi M; Montorsi F
    BJU Int; 2012 Mar; 109(5):678-84. PubMed ID: 21777363
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
    Freedland SJ; Terris MK; Platz EA; Presti JC
    Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy.
    Mandel P; Kretschmer A; Chandrasekar T; Nguyen HG; Buchner A; Stief CG; Tilki D
    Urol Oncol; 2014 Apr; 32(3):297-302. PubMed ID: 24332640
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Asian J Androl; 2020; 22(3):323-329. PubMed ID: 31347517
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.
    Rieken M; Shariat SF; Kluth LA; Fajkovic H; Rink M; Karakiewicz PI; Seitz C; Briganti A; Rouprêt M; Loidl W; Trinh QD; Bachmann A; Pourmand G
    Eur Urol; 2015 Dec; 68(6):949-56. PubMed ID: 26050111
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
    Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
    Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.
    ; Jayachandran J; Aronson WJ; Terris MK; Presti JC; Amling CL; Kane CJ; Freedland SJ
    BJU Int; 2008 Sep; 102(8):964-8. PubMed ID: 18691176
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy.
    Salomon G; Isbarn H; Budaeus L; Schlomm T; Briganti A; Steuber T; Heinzer H; Haese A; Graefen M; Karakiewicz PI; Huland H; Chun F
    J Sex Med; 2009 Feb; 6(2):498-504. PubMed ID: 19143908
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy.
    Mallah KN; DiBlasio CJ; Rhee AC; Scardino PT; Kattan MW
    Cancer; 2005 May; 103(10):2030-4. PubMed ID: 15822118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.